RANDOMIZED COMPARISON OF IBRUTINIB <i>VERSUS</i> OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE(™) TRIAL

Дата публикации: 27-08-2026 00:00:00

RANDOMIZED COMPARISON OF IBRUTINIB VERSUS OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE(™) TRIAL

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	ABT-199 (GDC-0199) COMBINED WITH RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INTERIM RESULTS OF A PHASE 1B STUDY	0	2.3	27-08-2026
2	NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	0	5	27-08-2026
3	PHASE 1B TRIAL OF AVL-292, A COVALENT INHIBITOR OF BRUTON'S TYROSINE KINASE (BTK), IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND B-NON-HODGKIN LYMPHOMA (B-NHL)	0	6.62	27-08-2026
4	Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors	0	5.21	27-08-2026
5	Pharmacokinetics, lineage identity, and trafficking of ex vivo expanded polyclonal regulatory T cells in a prospective randomized clinical trial of kidney transplant recipients with allograft inflammation	0	9.14	27-08-2026
6	Exercise Performance With Aficamten vs Metoprolol in oHCM	0	6.05	01-08-2026
7	Mesenchymal Stem Cells for Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant	0	7.27	01-02-2024
8	Highly Specific Inhibitor for Syk Induces Chronic Lymphocytic Leukemia Cell Apoptosis	0	2.5	27-08-2026
9	Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer	0	14.28	01-01-2025
10	Individualized Stereotactic Ablative Radiotherapy for Lung Tumors	0	6.6	01-11-2023

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 2.29. Источник: escholarship.org.